Osiris Therapeutics Inc. (OSIR)

[surf1944]

7:07AM Osiris Therapeutics receives title of european orphan drug designation for Prochymal (OSIR) 7.02 : Co announced today that the European Medicines Agency has designated Osiris as the Orphan Drug title holder for Prochymal. The EU Commission adopted the decision to transfer the designation of Prochymal (ex-vivo cultured adult human mesenchymal stem cells) as an orphan medicinal product under Regulation (EC) No 141/2000 of the European Parliament and of the Council. The Decision will appear in the EU Community Register of Orphan Medicinal Products.